Silence Therapeutics plc
SLN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479615
No open-market purchases or sales by Silence Therapeutics plc insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $236.2M in total; no superinvestor holds it.
Other share classesSLNCF
Q3 2023 vs. Q2 2023
How the institutions holding Silence Therapeutics plc changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 29 | 28 | −1 |
| Shares | 19.2M | 19.7M | +491.5K (+2.6%) |
| Value | $101.8M | $187.6M | +$85.8M (+84.3%) |
New holders (4)
Institutions that held Silence Therapeutics plc at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Lynx1 Capital Management LP | 235,787 | $2.32M | 1.53% |
| Lazard Asset Management LLC | 2,170 | $20.0K | 0.00% |
| Qube Research & Technologies Ltd | 178 | $1.75K | 0.00% |
| Rhumbline Advisers | 5 | $49 | 0.00% |
Sold out (5)
Institutions that held Silence Therapeutics plc at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Point72 Asset Management, L.P. | 86,700 | $476.9K |
| AXA S.A. | 58,624 | $322.4K |
| Millennium Management LLC | 22,832 | $125.6K |
| Tower Research Capital LLC (TRC) | 800 | $4.40K |
| Advisor Group Holdings, Inc. | 5 | $27 |